Clinical-stage biopharma developing antibodies targeting soluble amyloid beta oligomers for Alzheimer's disease. [BIOTECH-2026-10-04]
Search transcripts, quotes, and verified statements from every Acumen Pharmaceuticals executive via our platform or API.